Carol O’Hear

3.4k total citations · 1 hit paper
58 papers, 2.4k citations indexed

About

Carol O’Hear is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Carol O’Hear has authored 58 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 15 papers in Genetics. Recurrent topics in Carol O’Hear's work include Cancer Immunotherapy and Biomarkers (25 papers), CAR-T cell therapy research (21 papers) and Monoclonal and Polyclonal Antibodies Research (12 papers). Carol O’Hear is often cited by papers focused on Cancer Immunotherapy and Biomarkers (25 papers), CAR-T cell therapy research (21 papers) and Monoclonal and Polyclonal Antibodies Research (12 papers). Carol O’Hear collaborates with scholars based in United States, Spain and France. Carol O’Hear's co-authors include Marcella Fassò, Luciana Molinero, Indrani Sarkar, Fadi Braiteh, Leisha A. Emens, Michael S. Gordon, William Grossman, Joseph P. Eder, Jean‐Pierre Delord and Philippe A. Cassier and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Carol O’Hear

58 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer

2018 567 citations Leisha A. Emens, Cristina Cruz et al. profile →

Peers

Countries citing papers authored by Carol O’Hear

Since Specialization

Citations

This map shows the geographic impact of Carol O’Hear's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carol O’Hear with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carol O’Hear more than expected).

Fields of papers citing papers by Carol O’Hear

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carol O’Hear. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carol O’Hear. The network helps show where Carol O’Hear may publish in the future.

Co-authorship network of co-authors of Carol O’Hear

This figure shows the co-authorship network connecting the top 25 collaborators of Carol O’Hear. A scholar is included among the top collaborators of Carol O’Hear based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carol O’Hear. Carol O’Hear is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study 2021 ·Clinical Cancer Research ·Daniel P. Petrylak, Yohann Loriot, David R. Shaffer, Fadi Braiteh, John D. Powderly, Lauren C. Harshman, Paul Conkling, Jean‐Pierre Delord, Michael S. Gordon, Joseph W. Kim, Indrani Sarkar, Kobe Yuen, Edward E. Kadel, Sanjeev Mariathasan, Carol O’Hear, Sujata Narayanan, Marcella Fassò, Susheela Carroll, Thomas Powles	54
2	Mosunetuzumab, a Novel CD20/CD3 Bispecific Antibody, in Combination with CHOP Confers High Response Rates in Patients with Diffuse Large B-Cell Lymphoma 2020 ·Blood ·Tycel Phillips, Adam J. Olszewski, Javier Muñoz, Tae Min Kim, Dok Hyun Yoon, Richard Greil, Jason R. Westin, Ulrich Jaeger, Miguel Canales, Cindy Chen, Betsy Althaus, Carol O’Hear, (unknown), Yuying Xie, Ronald McCord, Enkhtsetseg Purev, (unknown)	37
3	Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts 2020 ·Blood ·Matthew J. Matasar, Chan Y. Cheah, Dok Hyun Yoon, Sarit Assouline, Nancy L. Bartlett, Matthew Ku, Pratyush Giri, Anna Johnston, Ian W. Flinn, André Goy, Dimitrios Tzachanis, Carol O’Hear, Shen Yin, Iris To, (unknown), Chi‐Chung Li, Brendan C. Bender, Elicia Penuel, Huang Huang, Lihua E. Budde	27
4	Unmet Medical Need Among Elderly Patients with Previously Untreated DLBCL Characterized Using Real-World Data in the United States 2020 ·Blood ·Ashwini Shewade, Adam J. Olszewski, (unknown), Andy Surinach, Gila Sellam, Lars Müeller, Carol O’Hear	6
5	Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer 2020 ·Clinical Lung Cancer ·Anne C. Chiang, Lecia V. Sequist, Jill Gilbert, Paul Conkling, (unknown), Judith Marcoux, Scott Gettinger, Marcin Kowanetz, Luciana Molinero, Carol O’Hear, Marcella Fassò, Sivuonthanh Lam, Michael S. Gordon	17
6	Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab 2019 ·Clinical Cancer Research ·Omid Hamid, Luciana Molinero, Christopher R. Bolen, Jeffrey A. Sosman, Eva Muñoz‐Couselo, Harriet M. Kluger, David F. McDermott, John D. Powderly, Indrani Sarkar, Marcus Ballinger, Marcella Fassò, Carol O’Hear, Daniel S. Chen, Priti S. Hegde, F. Stephen Hodi	58
7	Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers 2019 ·Gynecologic Oncology ·Joyce F. Liu, Michael S. Gordon, Jennifer Veneris, Fadi Braiteh, Ani Sarkis Balmanoukian, Joseph P. Eder, Ana Oaknin, Erika Hamilton, Yulei Wang, Indrani Sarkar, Luciana Molinero, Marcella Fassò, Carol O’Hear, Yvonne G. Lin, Leisha A. Emens	101
8	MA15.02 Long-Term Safety and Clinical Activity Results from a Phase Ib Study of Erlotinib Plus Atezolizumab in Advanced NSCLC 2018 ·Journal of Thoracic Oncology ·Charles M. Rudin, Andrés Cervantes, Afshin Dowlati, Benjamin Besse, Brigette Ma, Daniel B. Costa, Peter Schmid, Rebecca S. Heist, Victoria Villaflor, Indrani Sarkar, Genevive Hernandez, Paul Foster, Jessica Spahn, Carol O’Hear, Scott Gettinger	26
9	Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study 2018 ·Lung Cancer ·Shirish M. Gadgeel, Rimas V. Lukas, Jerome H. Goldschmidt, Paul Conkling, Keunchil Park, Diego Cortinovis, Filippo de Marinis, Achim Rittmeyer, Jyoti D. Patel, Joachim von Pawel, Carol O’Hear, (unknown), Sylvia Hu, Marcus Ballinger, Alan Sandler, Mayank Gandhi, L. Fehrenbacher	132
10	Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial 2018 ·Annals of Oncology ·A. Dimitrios Colevas, Rastislav Bahleda, Fadi Braiteh, Ani Sarkis Balmanoukian, Irene Braña, Nicole G. Chau, Indrani Sarkar, Luciana Molinero, William Grossman, Fairooz F. Kabbinavar, Marcella Fassò, Carol O’Hear, John D. Powderly	107
11	Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma 2018 ·Journal of Neuro-Oncology ·Rimas V. Lukas, Jordi Rodón, Kevin Becker, Eric T. Wong, Kent C. Shih, Mehdi Touat, Marcella Fassò, Stuart Osborne, Luciana Molinero, Carol O’Hear, William Grossman, Joachim M. Baehring	112
12	Abstract 2986: Atezolizumab in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses 2017 ·Cancer Research ·Peter Schmid, Cristina Cruz, Fadi S. Braiteh, Joseph P. Eder, Sara M. Tolaney, Irene Kuter, Rita Nanda, Cathie T. Chung, Philippe A. Cassier, Jean‐Pierre Delord, Michael S. Gordon, Yijin Li, Bo Liu, Carol O’Hear, Marcella Fassò, Luciana Molinero, Leisha A. Emens	92
13	Long-Term Safety and Clinical Outcomes of Atezolizumab in Head and Neck Cancer: Phase Ia Trial Results 2017 ·Annals of Oncology ·Rastislav Bahleda, Fadi S. Braiteh, Ani Sarkis Balmanoukian, Irene Braña, F. Stephen Hodi, Lawrence Garbo, (unknown), Luciana Molinero, Carol O’Hear, Xiaoyan Shen, A. Dimitrios Colevas	21
14	P3.02c-046 Safety, Clinical Activity and Biomarker Results from a Phase Ib Study of Erlotinib plus Atezolizumab in Advanced NSCLC 2017 ·Journal of Thoracic Oncology ·Charles M. Rudin, Andrés Cervantes, Afshin Dowlati, Benjamin Besse, Brigette Ma, Daniel B. Costa, Peter Schmid, Rebecca S. Heist, Victoria Villaflor, Indrani Sarkar, Mahrukh Huseni, Paul Foster, Carol O’Hear, Scott Gettinger	11
15	P2.03b-014 Atezolizumab in Advanced NSCLC Patients with Baseline Brain Metastases: A Pooled Cohort Safety Analysis 2017 ·Journal of Thoracic Oncology ·Rimas V. Lukas, Mayank Gandhi, Carol O’Hear, Sylvia Hu, (unknown), Jyoti D. Patel	3
16	Safety, clinical activity and biomarkers of atezolizumab (atezo) in advanced ovarian cancer (OC) 2016 ·Annals of Oncology ·J. R. Infante, Fadi Braiteh, Leisha A. Emens, Ani Sarkis Balmanoukian, Ana Oaknin, (unknown), (unknown), Luciana Molinero, Marcella Fassò, Carol O’Hear, Michael S. Gordon	36
17	PS01.62: Long-Term Safety and Clinical Activity of Atezolizumab Monotherapy in Metastatic NSCLC: Final Results from a Phase Ia Study 2016 ·Journal of Thoracic Oncology ·Michael S. Gordon, Roy S. Herbst, Leora Horn, Jean‐Charles Soria, Leena Gandhi, Enriqueta Felip, Lecia V. Sequist, David R. Spigel, Scott Antonia, Ani Sarkis Balmanoukian, Philippe A. Cassier, Bo Liu, Marcin Kowanetz, Carol O’Hear, Marcella Fassò, Alan Sandler, Scott Gettinger	2
18	Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC) 2015 ·Journal for ImmunoTherapy of Cancer ·Thomas Powles, Dorothee Nickles, Eliezer M. Van Allen, Colombe Chappey, Wei Zou, Marcin Kowanetz, Edward E. Kadel, Mitchell Denker, Zachary Boyd, Nicholas J. Vogelzang, Joseph Kim, Joaquim Bellmunt, Yohann Loriot, Charles G. Drake, Carol O’Hear, Marcella Fassò, Priti S. Hegde, Sanjeev Mariathasan	11
19	Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia 2014 ·Haematologica ·Carol O’Hear, (unknown), Ingo Schubert, Georg H. Fey, Terrence L. Geiger	87
20	Antibody Buffering in the Brain 2006 ·Journal of Molecular Biology ·Carol O’Hear, Jefferson Foote	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact